Related references
Note: Only part of the references are listed.Sputnik V COVID-19 vaccine candidate appears safe and effective Comment
Ian Jones et al.
LANCET (2021)
Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial
Francois-Xavier Lescure et al.
LANCET RESPIRATORY MEDICINE (2021)
Access to and equitable distribution of COVID-19 vaccine in low-income countries
Krishna Prasad Acharya et al.
NPJ VACCINES (2021)
Perspectives on RNA Vaccine Candidates for COVID-19
Pobitra Borah et al.
FRONTIERS IN MOLECULAR BIOSCIENCES (2021)
Developmental Landscape of Potential Vaccine Candidates Based on Viral Vector for Prophylaxis of COVID-19
Rajashri Bezbaruah et al.
FRONTIERS IN MOLECULAR BIOSCIENCES (2021)
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Chaolin Huang et al.
LANCET (2020)
Current pharmacological treatments for COVID-19: What's next?
Cristina Scavone et al.
BRITISH JOURNAL OF PHARMACOLOGY (2020)
Cytokine storm and immunomodulatory therapy in COVID-19: Role of chloroquine and anti-IL-6 monoclonal antibodies
Ming Zhao
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2020)
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial
Philippe Gautret et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2020)
Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency
Calvin J. Gordon et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2020)
Tocilizumab treatment in COVID-19: A single center experience
Pan Luo et al.
JOURNAL OF MEDICAL VIROLOGY (2020)
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial
Yeming Wang et al.
LANCET (2020)
COVID-19 vaccines: breaking record times to first-in-human trials
Young Chan Kim et al.
NPJ VACCINES (2020)
Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study
Qingxian Cai et al.
ENGINEERING (2020)
A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19
B. Cao et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
COVID-19 infection: Origin, transmission, and characteristics of human coronaviruses
Muhammad Adnan Shereen et al.
JOURNAL OF ADVANCED RESEARCH (2020)
No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection
J. M. Molina et al.
MEDECINE ET MALADIES INFECTIEUSES (2020)
Chloroquine and hydroxychloroquine in the treatment of malaria and repurposing in treating COVID-19
Zi-Ning Lei et al.
PHARMACOLOGY & THERAPEUTICS (2020)
A short review on antibody therapy for COVID-19
G. Venkat Kumar et al.
NEW MICROBES AND NEW INFECTIONS (2020)
Discovering drugs to treat coronavirus disease 2019 (COVID-19)
Liying Dong et al.
DRUG DISCOVERIES AND THERAPEUTICS (2020)
T-705 (favipiravir) and related compounds: Novel broad-spectrum inhibitors of RNA viral infections
Yousuke Furuta et al.
ANTIVIRAL RESEARCH (2009)